Regeneron Pharmaceuticals

Get in the Ideas Business.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible.
As we work together to discover, invent, and develop biopharmaceutical medicines, we’re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health.
So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in.

Company Growth (employees)
Type
Public
HQ
Tarrytown, US
Founded
1988
Size (employees)
5,400 (est)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike

Regeneron Pharmaceuticals Data and Metrics

Regeneron Pharmaceuticals Financial Metrics

Regeneron Pharmaceuticals's revenue was reported to be $4.9 b in FY, 2016 which is a 18% increase from the previous period.
USD

Revenue (FY, 2016)

4.9 b

Revenue growth (FY, 2015 - FY, 2016), %

18%

Gross profit (FY, 2016)

4.7 b

Gross profit margin (FY, 2016), %

96%

Net income (FY, 2016)

895.5 m

EBIT (FY, 2016)

1.3 b

Market capitalization (26-Jun-2017)

54.5 b

Closing share price (26-Jun-2017)

517.3

Cash (31-Dec-2016)

535.2 m
Regeneron Pharmaceuticals's current market capitalization is $54.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.1 b2.8 b4.1 b4.9 b

Revenue growth, %

34%46%18%

Cost of goods sold

118 m129 m241.7 m194.6 m

Gross profit

2 b2.7 b3.9 b4.7 b

Gross profit Margin, %

94%95%94%96%

Operating expense total

1.2 b1.9 b2.6 b3.5 b

EBIT

760 m838.4 m1.3 b1.3 b

EBIT margin, %

36%30%31%27%

Interest expense

46.4 m37.4 m14.2 m7.2 m

Pre tax profit

713.4 m775.7 m1.2 b1.3 b

Income tax expense

(289 m)(427.7 m)(589 m)(434.3 m)

Net Income

424.4 m348.1 m636.1 m895.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

535.6 m648.7 m809.1 m535.2 m

Inventories

70.4 m128.9 m238.6 m399.4 m

Current Assets

1.8 b2.2 b2.9 b3.2 b

PP&E

2.1 b

Total Assets

3 b3.9 b5.6 b7 b

Accounts Payable

250.9 m484.2 m644.1 m879.1 m

Current Liabilities

298.8 m654.7 m811.2 m1.2 b

Common Stock

2 k2 k2 k2 k

Additional Paid-in Capital

2 b2.4 b3.1 b3 b

Retained Earnings

(92.7 m)255.4 m852.7 m1.7 b

Total Equity

2 b2.5 b3.7 b4.4 b

Financial Leverage

1.5 x1.5 x1.5 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

424.4 m348.1 m636.1 m895.5 m

Depreciation and Amortization

41.2 m52.7 m74.9 m104.7 m

Inventories

(48 m)(61 m)(110 m)(150 m)

Cash From Operating Activities

583.6 m743.2 m1.3 b1.5 b

Capital Expenditures

(156.3 m)(333 m)(677.9 m)(511.9 m)

Cash From Investing Activities

(355.5 m)

Cash From Financing Activities

(209.3 m)(262.8 m)(700.4 m)

Interest Paid

23.8 m20.6 m10.6 m5.5 m

Income Taxes Paid

59.8 m276.1 m481.4 m

Free Cash Flow

740 m1.1 b2 b2 b
USDY, 2016

Revenue/Employee

1 m

Financial Leverage

1.6 x

Regeneron Pharmaceuticals Market Value History

Regeneron Pharmaceuticals Median Salaries

Source: 186 public H-1B filings from Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Online and Social Media Presence

Regeneron Pharmaceuticals News and Updates

Regeneron Pharmaceuticals Company Life and Culture

You may also be interested in